Non-hodgkin lenfoma ve hodgkin hastalığında 10 yıllık izlemde klinik bulgular ve tedavi sonuçlarının değerlendirilmesi

Abstract

ÖZET 1985-1995 yılları arasında GATA Tıbbi Onkoloji Kliniğinde tanısı konmuş 68 NHL'li ve 49 HH'lı olgu değerlendirmeye alındı. Değerlendirmeye alınan NHL'li olgularda median yaş 40.5 (19-79), HH'lı olgularda median yaş 21 (14-66) idi. NHL'de hastalık 54 olguda lenfatik, 14 olguda ekstralenfatik olarak başlamış idi. NHL'li olguların 4'ü low grade, 37'si intermediate, 27'si high grade idi. NHL'de 22 hasta evre I, 14 hasta evre II, 7 hasta evre III, 25 hasta evre IV idi. HH'de 10 hasta evre I, 9 hasta evre II, 24 hasta evre III, 6 hasta evre IV idi. B semptomları NHL'li hastaların %44. Tinde, HH'li hastaların %60.4'ünde bulunmakta idi. HH'li hastaların %14.3'ü (7) LZT, %28.5'i (14) NST, %49'u (24) MST ve %8.2'si (4) LFT idi. Toplam sağ kalım olasılıkları Kaplan-Meier yöntemi ile hesaplanmıştır. NHL'de maksimum izlem süresi 123 ay olup median izlem süresi 82.1 aydır. Toplam sağ kalım olasılıkları 6 aylık takipte %95.3, 12 aylık takipte %72.8, 24 aylık takipte %63.7, 48 aylık takipte %56.7, 60 aylık takipte %51.6, 120 aylık takipte %42.9 olarak bulunmuştur. HH'de maksimum izlem süresi 127 ay olup median izlem süresi 107.2 aydır. Toplam sağ kalım olasılıkları 6 aylık takipte %97.9, 12 aylık takipte %95.6, 24 aylık takipte %95.6, 48 aylık takipte %87.8, 60 aylık takipte %78.1, 120 aylık takipte %78.1 olarak bulunmuştur. Bu sonuçlar literatürde belirtilenlerle benzerlik göstermektedir.

SUMMARY Sixty-eight patients with NHL and 49 patients with HD, who were diagnosed and followed-up at Gülhane Training Hospital, Department of Medical Oncology, were included into the study. Median age was 40.5 (19-79) for NHL patients and 21 (14-66) for HD patients. In NHL group, the disease initiated at extralymphatic tissues in 14 patients and at lymphatic tissues in 54 patients. Four of NHL patients had low grade, 37 had intermediate, and 27 had high grade disease. Twenty-two patients had stage I, 14 had stage II, 7 had stage III, and 25 had stage IV disease. Ten patients with HD had stage I, 9 had stage II, 24 had stage III, and 6 had stage IV disease. B symptoms were present in 44.1% of NHL patients and 60% of HD patients. Distribution of the HD patients according to the subtype of disease was as follows; 14.3% had lymphocyte predominant type, 28.5% had nodular sclerosing type, 49% had mixed cellularity type, and 8.. 2% had lymphocyte depletion type. Maximum follow-up time was 123 months, and median follow-up time was 82.1 months for NHL patients. Overall survival rate was 93.5% for 6 months, 72.8% for 12 months, 63.7% for 24 months, 56.7% for 48 months, 51.6% for 60 months, 42.9% for 120 months. Maximum follow-up time was 127 months, and median follow-up time was 107.2 months for HD patients. Overall survival rate was 97.9% for 6 months, 95.6% for 12 months, 95.6% for 24 months, 87.8% for 48 months, 78.1 % for 60 months, 78.1 % for 120 months. These results were correlated with the literature. 29